Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313626972> ?p ?o ?g. }
- W4313626972 endingPage "105523" @default.
- W4313626972 startingPage "105523" @default.
- W4313626972 abstract "Despite available therapies, persistently active and corticosteroid-dependent Systemic Lupus Erythematosus (SLE) represent a significant therapeutic challenge. The purpose of this systematic review was to provide an updated view of targeted therapies currently in clinical development in SLE, with a special focus on the most promising ones.We performed a systematic review of targeted therapies in clinical development in SLE in clinicaltrials.gov (search date: 28th of August 2022). Targeted therapies (defined as drugs specifically designed to block certain molecules, receptors, or pathways involved in the development of SLE) were extracted. For each investigational drug, we considered only the study at the most advanced stage of clinical development.The systematic review yielded a total of 92 targeted therapies (58 biological DMARDs [bDMARDs] and 34 targeted synthetic [ts]DMARDs) assessed in a total of 203 clinical trials. The candidate drugs reached phase I (n=20), Ia/IIb (n=6), phase II (n=51), phase II/III (n=1), phase III (n=13) and phase IV (n=1). These trials were reported as recruiting (n=31), active but not recruiting (n=8), not yet recruiting (n=4), enrolling by invitation (n=2), completed (n=31), prematurely terminated (n=12) and withdrawn in 1 (status unknown in 3). The main investigational drugs for SLE target inflammatory cytokines, chemokines or their receptors (n=19), intracellular signaling pathways (n=18), B cells (n=14) or plasma cells (n=7),T/B cells co-stimulation molecules (n=10), complement molecules (n=5),T lymphocytes (n=2), plasmacytoid dendritic cells (n=2), as well as various other immune targets (n=15).The pipeline of investigational drugs in SLE is highly diversified and will hopefully enable more optimal Treat-To-Target with the goal of disease modification. Companion biomarkers will be needed to better characterized SLE heterogeneity and optimize treatment selection at the individual-patient level." @default.
- W4313626972 created "2023-01-07" @default.
- W4313626972 creator A5029466909 @default.
- W4313626972 creator A5038884673 @default.
- W4313626972 creator A5045141907 @default.
- W4313626972 creator A5070589258 @default.
- W4313626972 creator A5082120478 @default.
- W4313626972 date "2023-03-01" @default.
- W4313626972 modified "2023-09-30" @default.
- W4313626972 title "New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review" @default.
- W4313626972 cites W1688265474 @default.
- W4313626972 cites W1989273660 @default.
- W4313626972 cites W1994649501 @default.
- W4313626972 cites W2046330020 @default.
- W4313626972 cites W2091129202 @default.
- W4313626972 cites W2098881967 @default.
- W4313626972 cites W2105733675 @default.
- W4313626972 cites W2106273198 @default.
- W4313626972 cites W2117491442 @default.
- W4313626972 cites W2131457901 @default.
- W4313626972 cites W2136149088 @default.
- W4313626972 cites W2146853551 @default.
- W4313626972 cites W2162841077 @default.
- W4313626972 cites W2409438019 @default.
- W4313626972 cites W2495097377 @default.
- W4313626972 cites W2556359407 @default.
- W4313626972 cites W2766697888 @default.
- W4313626972 cites W2806152658 @default.
- W4313626972 cites W2823373950 @default.
- W4313626972 cites W2901041673 @default.
- W4313626972 cites W2901743623 @default.
- W4313626972 cites W2909900992 @default.
- W4313626972 cites W2910913933 @default.
- W4313626972 cites W2927871970 @default.
- W4313626972 cites W2930005839 @default.
- W4313626972 cites W2944570735 @default.
- W4313626972 cites W2967918238 @default.
- W4313626972 cites W2969802847 @default.
- W4313626972 cites W2982474992 @default.
- W4313626972 cites W2983004004 @default.
- W4313626972 cites W2995521654 @default.
- W4313626972 cites W3044322808 @default.
- W4313626972 cites W3084952974 @default.
- W4313626972 cites W3085025551 @default.
- W4313626972 cites W3086471819 @default.
- W4313626972 cites W3111304448 @default.
- W4313626972 cites W3113129718 @default.
- W4313626972 cites W3123843462 @default.
- W4313626972 cites W3130819905 @default.
- W4313626972 cites W3132925486 @default.
- W4313626972 cites W3158669775 @default.
- W4313626972 cites W3164255840 @default.
- W4313626972 cites W3164417236 @default.
- W4313626972 cites W3197001173 @default.
- W4313626972 cites W3202510981 @default.
- W4313626972 cites W3207980966 @default.
- W4313626972 cites W4200117851 @default.
- W4313626972 cites W4210435204 @default.
- W4313626972 cites W4210750360 @default.
- W4313626972 cites W4211012592 @default.
- W4313626972 cites W4220810697 @default.
- W4313626972 cites W4225095275 @default.
- W4313626972 cites W4280627367 @default.
- W4313626972 cites W4288050416 @default.
- W4313626972 cites W4294908091 @default.
- W4313626972 doi "https://doi.org/10.1016/j.jbspin.2023.105523" @default.
- W4313626972 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36623799" @default.
- W4313626972 hasPublicationYear "2023" @default.
- W4313626972 type Work @default.
- W4313626972 citedByCount "9" @default.
- W4313626972 countsByYear W43136269722023 @default.
- W4313626972 crossrefType "journal-article" @default.
- W4313626972 hasAuthorship W4313626972A5029466909 @default.
- W4313626972 hasAuthorship W4313626972A5038884673 @default.
- W4313626972 hasAuthorship W4313626972A5045141907 @default.
- W4313626972 hasAuthorship W4313626972A5070589258 @default.
- W4313626972 hasAuthorship W4313626972A5082120478 @default.
- W4313626972 hasConcept C126322002 @default.
- W4313626972 hasConcept C203014093 @default.
- W4313626972 hasConcept C2776912625 @default.
- W4313626972 hasConcept C2779134260 @default.
- W4313626972 hasConcept C535046627 @default.
- W4313626972 hasConcept C71924100 @default.
- W4313626972 hasConcept C98274493 @default.
- W4313626972 hasConceptScore W4313626972C126322002 @default.
- W4313626972 hasConceptScore W4313626972C203014093 @default.
- W4313626972 hasConceptScore W4313626972C2776912625 @default.
- W4313626972 hasConceptScore W4313626972C2779134260 @default.
- W4313626972 hasConceptScore W4313626972C535046627 @default.
- W4313626972 hasConceptScore W4313626972C71924100 @default.
- W4313626972 hasConceptScore W4313626972C98274493 @default.
- W4313626972 hasFunder F4320307770 @default.
- W4313626972 hasFunder F4320307773 @default.
- W4313626972 hasFunder F4320338413 @default.
- W4313626972 hasIssue "2" @default.
- W4313626972 hasLocation W43136269721 @default.
- W4313626972 hasLocation W43136269722 @default.
- W4313626972 hasOpenAccess W4313626972 @default.